Review
Open access
Aug 2026
Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy
Daratumumab-based therapy may induce remission and facilitate HSCT bridging in selected patients, but findings remain hypothesis-generating because evidence is mainly from case reports and small series.
A. Al-Mashdali, Mujahid O. Abdelraof, Monia Ibrahim et al.
· Therapeutic Advances in Hema... · 0 citations